Marksans Pharma Ltd's Q3FY25 Quarter Results
- 12 Feb 2025
Result Summary
- Marksans Pharma Ltd reported a 8.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.1%.
- Its expenses for the quarter were up by 7.2% QoQ and 18.4% YoY.
- The net profit increased 7.5% QoQ and increased 26.6% YoY.
- The earnings per share (EPS) of Marksans Pharma Ltd stood at 2.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 709.70 | 652.98 | 590.93 | 8.7% | 20.1% |
Total Expenses | 566.44 | 528.38 | 478.26 | 7.2% | 18.4% |
Profit Before Tax | 143.26 | 124.60 | 112.66 | 15.0% | 27.2% |
Tax | 38.19 | 26.84 | 29.69 | 42.3% | 28.6% |
Profit After Tax | 105.06 | 97.76 | 82.97 | 7.5% | 26.6% |
Earnings Per Share | 2.30 | 2.10 | 1.80 | 9.5% | 27.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Marksans Pharma Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of generic pharmaceutical formulations. The company operates primarily in the healthcare sector, offering a range of pharmaceutical products across various therapeutic segments. Marksans Pharma's product portfolio includes over-the-counter (OTC) products, prescription drugs, and active pharmaceutical ingredients (APIs). Known for its strong focus on research and development, the company aims to provide affordable and high-quality pharmaceutical solutions. Recent strategic initiatives and developments in the company are not provided in the data available, hence further specific updates are not included.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Marksans Pharma Ltd reported a total income of ₹709.70 crores. This represents an increase of 8.7% from the previous quarter (Q2FY25), which recorded total income of ₹652.98 crores. Compared to the same quarter in the previous fiscal year (Q3FY24), where total income was ₹590.93 crores, there is a year-over-year growth of 20.1%. This data indicates consistent revenue growth on both a quarterly and annual basis. The observed increase in total income over these periods reflects the company's operational performance and market demand for its products.
Profitability
Marksans Pharma Ltd's profitability metrics for Q3FY25 show a positive trend. The profit before tax for this quarter was ₹143.26 crores, up 15.0% from ₹124.60 crores in Q2FY25. Year-over-year, the profit before tax increased by 27.2% from ₹112.66 crores in Q3FY24. The profit after tax for Q3FY25 was reported at ₹105.06 crores, which is a 7.5% increase from the ₹97.76 crores recorded in the previous quarter and a 26.6% rise from ₹82.97 crores in Q3FY24. The company's earnings per share (EPS) also showed growth, at ₹2.30 in Q3FY25 compared to ₹2.10 in Q2FY25, marking a quarterly increase of 9.5%. Year-over-year, EPS rose by 27.8% from ₹1.80 in Q3FY24. These figures reflect an upward trajectory in the company's profitability over the analyzed periods.
Operating Metrics
The total expenses for Marksans Pharma Ltd in Q3FY25 were ₹566.44 crores, which shows a 7.2% increase from the previous quarter's (Q2FY25) expenses of ₹528.38 crores. Comparing year-over-year, there is an 18.4% rise from the expenses of ₹478.26 crores in Q3FY24. The tax expenses for Q3FY25 were ₹38.19 crores, reflecting a significant 42.3% increase from Q2FY25's tax of ₹26.84 crores, and a 28.6% rise from ₹29.69 crores in Q3FY24. These operating metrics indicate changes in the cost structure and tax obligations over the quarters and year. The data illustrates how the company has managed its operational costs and tax liabilities in the context of its growing income and profitability.
